Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, Russian Federation.
Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, Russian Federation; Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russian Federation.
Adv Cancer Res. 2020;145:49-97. doi: 10.1016/bs.acr.2019.11.002. Epub 2019 Dec 20.
As basic research into GPCR signaling and its association with disease has come into fruition, greater clarity has emerged with regards to how these receptors may be amenable to therapeutic intervention. As a diverse group of receptor proteins, which regulate a variety of intracellular signaling pathways, research in this area has been slow to yield tangible therapeutic agents for the treatment of a number of diseases including cancer. However, recently such research has gained momentum based on a series of studies that have sought to define GPCR proteins dynamics through the elucidation of their crystal structures. In this chapter, we define the approaches that have been adopted in developing better therapeutics directed against the specific parts of the receptor proteins, such as the extracellular and the intracellular domains, including the ligands and auxiliary proteins that bind them. Finally, we also briefly outline how GPCR-derived signaling transduction pathways hold great potential as additional targets.
随着对 GPCR 信号及其与疾病的关联的基础研究取得成果,人们对这些受体如何能够进行治疗干预有了更清晰的认识。作为一组多样化的受体蛋白,它们调节多种细胞内信号通路,该领域的研究一直进展缓慢,难以找到针对包括癌症在内的许多疾病的切实可行的治疗药物。然而,最近的一系列研究通过阐明其晶体结构来定义 GPCR 蛋白动力学,为这方面的研究提供了动力。在本章中,我们定义了为开发针对受体蛋白特定部分(如细胞外和细胞内结构域)的更好治疗方法而采用的方法,包括结合它们的配体和辅助蛋白。最后,我们还简要概述了 GPCR 衍生的信号转导途径如何作为额外的靶标具有巨大的潜力。